Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

duligotuzumab (MEHD7945A)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

EGFR inhibitor, HER3 inhibitor

Related drugs:

‹

zenocutuzumab-zbco (16)

Ac-225 ErbB3 targeted radiotherapy (4)

177Lu-HER3 ARC (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

zenocutuzumab-zbco (16)

Ac-225 ErbB3 targeted radiotherapy (4)

177Lu-HER3 ARC (0)

›